Odstawienie nilotynibu u pacjentki z przewlekłą białaczką szpikową i małopłytkowością będącą powikłaniem leczenia imatynibem

Treatment of chronic myelogenous leukemia (CML) with BCR-ABL1 tyrosine kinase inhibitors (TKI) significantly changed the course of this disease and had a positive effect on prognosis. Thanks to targeted therapy, CML has transformed from an incurable disease with limited treatment options into a more indolent disease with survival comparable to that of the general population. Moreover, there is a certain group of patients who can be permanently discontinued from treatment. This is especially important in the case of TKI-related side effects, which may reduce the patient’s quality of life. In this article we present a case report of CML patient who developed immune thrombocytopenia after imatinib treatment. In the second-line nilotinib was used. Despite dose reduction (because of decreased platelet level) treatment with nilotinib allowed for deepening of the molecular response. Thanks to this, the patient turned out to be a suitable candidate for treatment discontinuation after a few years.